RT Journal Article
SR Electronic
T1 Antibiotic-associated neutropenia is marked by depletion of intestinal <em>Lachnospiraceae</em> in pediatric patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.04.25.24306386
DO 10.1101/2024.04.25.24306386
A1 Fernandez-Sanchez, Josaura
A1 Rodgers, Rachel
A1 Maknojia, Arushana A.
A1 Shaikh, Nusrat
A1 Yan, Hannah
A1 Mejia, Marlyd E.
A1 Hendricks, Hope
A1 Jenq, Robert R.
A1 Reddy, Pavan
A1 Banerjee, Ritu
A1 Schraw, Jeremy M.
A1 Baldridge, Megan T.
A1 King, Katherine Y.
YR 2024
UL http://medrxiv.org/content/early/2024/04/27/2024.04.25.24306386.abstract
AB Hematologic side effects are associated with prolonged antibiotic exposure in up to 34% of patients. Neutropenia, reported in 10-15% of patients, increases the risk of sepsis and death. Murine studies have established a link between the intestinal microbiota and normal hematopoiesis. We sought to identify predisposing factors, presence of microbiota-derived metabolites, and changes in intestinal microbiota composition in otherwise healthy pediatric patients who developed neutropenia after prolonged courses of antibiotics. In this multi-center study, patients with infections requiring anticipated antibiotic treatment of two or more weeks were enrolled. Stool samples were obtained at the start and completion of antibiotics and at the time of neutropenia. We identified 10 patients who developed neutropenia on antibiotics and 29 controls matched for age, sex, race, and ethnicity. Clinical data demonstrated no association between neutropenia and type of infection or type of antibiotic used; however intensive care unit admission and length of therapy were associated with neutropenia. Reduced intestinal microbiome richness and decreased abundance of Lachnospiraceae family members correlated with neutropenia. Untargeted stool metabolomic profiling revealed several metabolites that were depleted exclusively in patients with neutropenia, including members of the urea cycle pathway, pyrimidine metabolism and fatty acid metabolism that are known to be produced by Lachnospiraceae. Our study confirms a relationship between intestinal microbiota disruption and abnormal hematopoiesis and identifies taxa and metabolites likely to contribute to microbiota-sustained hematopoiesis. As the microbiome is a key determinant of stem cell transplant and immunotherapy outcomes, these findings are likely to be of broad significance.Key PointsNeutropenia occurred in 17% of patients receiving prolonged antibiotic therapy.We found no association between neutropenia and type of infection or class of antibiotic used.Development of neutropenia after prolonged antibiotic treatment was associated with decreased prevalence of Lachnospiraceae and Lachnospiraceae metabolites such as citrulline.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by R01AI141716, R35HL155672, F31HL168921, F31HL147514, T32GM136554, and R31AI167538.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The IRBs of Baylor College of Medicine and Vanderbilt University gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors or online at: https://www.ebi.ac.uk/ena/browser/view/PRJEB72348 and https://data.mendeley.com/datasets/38z7h96km4/1 https://www.ebi.ac.uk/ena/browser/view/PRJEB72348 https://data.mendeley.com/datasets/38z7h96km4/1